WeVote
Log In

Bill

Bill

HB 1531

TO PROHIBIT PHARMACEUTICAL MANUFACTURERS FROM RESTRICTING OR LIMITING PRESCRIPTION MEDICATIONS TO A LIMITED DISTRIBUTION NETWORK OF OUT-OF-STATE PHARMACIES.

2025 Regular Session Introduced by Brandon Achor and 1 co-sponsor

Act 630 enhances Arkansas patients' access to medications by prohibiting manufacturers from limiting distribution to out-of-state pharmacies, boosting local pharmacy support.

Notification that HB1531 is now Act 630
0
WeVote Research Nonpartisan
Bill Summary · HB 1531

Summary of House Bill 1531 (Act 630)

Purpose and Intent

House Bill 1531, now known as Act 630, aims to enhance patient access to prescription medications in Arkansas by prohibiting pharmaceutical manufacturers from restricting or limiting the distribution of medications to a limited network of out-of-state pharmacies. The bill seeks to ensure that local pharmacies can provide patients with timely access to necessary medications, thereby promoting patient choice and safety.

Key Provisions

The bill introduces several significant changes to the Arkansas Code, specifically under Title 20, Chapter 64, Subchapter 1:

  1. Prohibition on Limited Distribution:

    • Pharmaceutical manufacturers are not allowed to limit the distribution of prescription medications to out-of-state pharmacies for more than three months after the launch of a new product.
    • Local pharmacies must be given access to these medications upon request, ensuring geographic diversity and inclusion of both for-profit and nonprofit pharmacies.

  2. Transparency and Oversight:

    • The bill mandates increased transparency in the supply chain of prescription medications, aiming to protect patient safety and ensure stable inventory for immediate and long-term care needs.
    • Pharmaceutical manufacturers must present any requests for extended limited distribution networks to the Arkansas State Board of Pharmacy for approval.

  3. Compliance and Penalties:

    • Manufacturers that fail to comply with the provisions of this act may face fines of $10,000 per day of noncompliance.
    • A compliance deadline is set for September 1, 2026, by which all pharmaceutical manufacturers must adhere to the new regulations.

  4. Public Health Considerations:

    • The bill emphasizes the importance of public health and safety, requiring that any limitations on distribution must not hinder the mission of promoting public welfare.

Affected Parties

  • Patients: The primary beneficiaries of this legislation are patients in Arkansas who will have improved access to prescription medications through local pharmacies.
  • Local Pharmacies: Pharmacies in Arkansas will gain the ability to procure medications directly from manufacturers, enhancing their role in patient care.
  • Pharmaceutical Manufacturers: These entities will face new regulations regarding the distribution of their products and may incur penalties for noncompliance.

Procedural Timeline

  • Introduced: February 19, 2025
  • Passed: April 9, 2025
  • Enrolled and Transmitted to Governor: April 10, 2025
  • Notification of Act: April 16, 2025

Conclusion

Act 630 represents a significant step towards improving prescription medication access in Arkansas, ensuring that local pharmacies can effectively serve their communities. By prohibiting restrictive distribution practices, the legislation aims to enhance patient choice, safety, and overall public health.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.